Hemp State Regulation: Navigating the Patchwork of U.S. Cannabis Laws

Executive Summary

Hemp regulation in the United States is fragmenting into a complex state-by-state patchwork as federal oversight remains limited and states impose their own restrictions on hemp-derived cannabinoids. The 2018 Farm Bill legalized hemp containing no more than 0.3% delta-9 THC on a dry weight basis, creating a federal framework that removed hemp from Schedule I of the Controlled Substances Act. However, the law explicitly preserved state authority to regulate hemp production and sales within their borders. As of July 2026, more than 35 states have enacted additional regulations targeting hemp-derived intoxicating cannabinoids including delta-8 THC, THCA, and HHC, creating a fragmented marketplace that challenges interstate commerce and forces operators to navigate conflicting compliance requirements. The regulatory divergence affects cultivators, processors, retailers, and consumers across a market estimated at $28 billion in 2025, with state-level restrictions ranging from outright bans to age limits, testing mandates, and potency caps. This topic hub provides comprehensive analysis of the evolving state-by-state regulatory landscape, the federal framework's limitations, market implications for operators, and the ongoing debate over whether hemp should remain federally permissive or face stricter oversight.

Why This Matters

The state-by-state fragmentation of hemp regulation affects thousands of businesses, millions of consumers, and billions of dollars in commerce while raising fundamental questions about federalism and public health. According to the Hemp Industries Association, the U.S. hemp industry employed approximately 328,000 workers across cultivation, processing, and retail sectors as of 2025. The regulatory uncertainty directly impacts multi-state operators who must maintain separate compliance programs for each jurisdiction, small businesses that lack resources to navigate complex state-specific requirements, and consumers who face inconsistent product availability and safety standards. State restrictions on hemp-derived cannabinoids have created a bifurcated market. In states like California and Colorado, hemp products containing intoxicating cannabinoids face the same regulatory framework as marijuana, including testing requirements, packaging standards, and licensed-only sales channels. In contrast, states like Florida and Texas have maintained more permissive frameworks while debating restrictions. The regulatory divergence has generated an estimated $400 million in additional compliance costs for multi-state hemp operators according to 2025 industry surveys. The debate extends beyond business interests to public health and consumer protection. State regulators cite concerns about unregulated intoxicating products sold in gas stations and convenience stores without age verification or potency disclosure. The FDA has issued warning letters to companies making unsubstantiated health claims about CBD and other hemp-derived cannabinoids but has not established a comprehensive regulatory framework for hemp-derived products in food, beverages, or dietary supplements. This federal regulatory gap has prompted states to act independently, creating the current patchwork. Agricultural stakeholders face particular challenges. Hemp farmers who cultivated crops expecting broad market access now confront state-level restrictions that limit their customer base. Processing facilities that extract cannabinoids must verify destination-state compliance before shipping products. Retailers in border regions report customer confusion about which products are legal in their home states. The fragmentation affects capital allocation decisions, with investors hesitant to fund multi-state expansion given regulatory uncertainty.

Background and History

Hemp regulation in the United States has evolved from federal prohibition to state-level experimentation and back to federal legalization with state opt-outs, creating the current fragmented landscape.

Pre-2014: Federal Prohibition Era

The Controlled Substances Act of 1970, codified at 21 U.S.C. § 812, classified marijuana as a Schedule I substance with no accepted medical use and high potential for abuse. The statute's definition of marijuana included all parts of the plant Cannabis sativa L., making no distinction between intoxicating marijuana and industrial hemp. This classification effectively prohibited hemp cultivation in the United States despite its historical use for fiber, seed, and oil production. From 1970 through 2013, U.S. hemp product manufacturers relied entirely on imported hemp biomass and derivatives, primarily from Canada and China. The Drug Enforcement Administration maintained that all cannabis cultivation required a DEA registration, which the agency did not issue for hemp production. This position remained unchanged for more than four decades despite advocacy from agricultural groups and industrial hemp proponents who argued that low-THC cannabis posed no intoxication risk and offered legitimate commercial applications.

2014: Agricultural Act Pilot Programs

The Agricultural Act of 2014, signed into law on February 7, 2014, created the first federal carve-out for hemp in Section 7606. The provision authorized state departments of agriculture and institutions of higher education to grow industrial hemp for research purposes in states that had legalized hemp cultivation. The law defined industrial hemp as Cannabis sativa L. containing no more than 0.3% THC on a dry weight basis, establishing the threshold that would later become the federal standard. Between 2014 and 2018, 41 states enacted legislation authorizing hemp pilot programs under the federal research exemption. These programs varied significantly in scope. Kentucky, Colorado, and Oregon developed robust frameworks with hundreds of licensed cultivators, while other states authorized only limited university research plots. The pilot program era generated critical data about cultivation practices, processing methods, and market demand that would inform the 2018 Farm Bill.

2018: Farm Bill Federal Legalization

The Agriculture Improvement Act of 2018, signed into law on December 20, 2018, fundamentally restructured federal hemp policy. Section 10113 removed hemp from the definition of marijuana in the Controlled Substances Act, explicitly legalizing hemp production and interstate commerce in hemp and hemp-derived products. The law defined hemp as Cannabis sativa L. and any part of the plant, including all derivatives, extracts, and cannabinoids, containing no more than 0.3% delta-9 THC on a dry weight basis. The 2018 Farm Bill transferred primary regulatory authority from the DEA to the U.S. Department of Agriculture, which was directed to establish a regulatory framework for hemp production. Critically, Section 10114 preserved state and tribal authority to prohibit or regulate hemp production within their jurisdictions. States could choose to submit regulatory plans to USDA for approval or allow USDA to regulate hemp production directly through a federal plan. The law also maintained FDA authority over hemp-derived products intended for human or animal consumption, creating an ongoing regulatory gap that persists as of 2026. The FDA has not established regulations for CBD in food, beverages, or dietary supplements, citing safety concerns about long-term consumption and potential drug interactions.

2019-2021: USDA Implementation and State Divergence

USDA published an interim final rule on October 31, 2019, establishing requirements for state and tribal hemp production plans. The rule required states to implement procedures for maintaining information on land where hemp is produced, testing THC concentration levels, disposing of non-compliant plants, and licensing hemp producers. The agency mandated testing within 15 days of anticipated harvest using DEA-registered laboratories, with a total THC measurement (delta-9 THC plus 87.7% of THCA) not exceeding 0.3%. The testing protocol proved controversial. Many cultivators reported that hemp plants could test compliant one day and non-compliant days later as THC levels fluctuated during the harvest window. The 15-day testing window and total THC calculation resulted in significant crop destruction. USDA data from 2020 indicated that approximately 20% of tested hemp lots exceeded the 0.3% threshold and required disposal. During this period, states began diverging in their approaches to hemp-derived cannabinoids. The emergence of delta-8 THC products in 2020 accelerated state-level regulatory action. Delta-8 THC, a minor cannabinoid that occurs naturally in hemp in trace amounts but can be synthesized from CBD through chemical conversion, produces intoxicating effects similar to delta-9 THC. Manufacturers argued that delta-8 THC derived from compliant hemp was federally legal under the 2018 Farm Bill. State regulators and law enforcement disagreed, arguing that intoxicating cannabinoids violated the spirit of hemp legalization.

2022-2024: Proliferation of State Restrictions

Between 2022 and 2024, more than 25 states enacted legislation restricting or banning hemp-derived intoxicating cannabinoids. The regulatory approaches varied significantly. Colorado enacted HB 22-1317 in May 2022, requiring hemp products containing detectable amounts of THC to be sold only through licensed marijuana dispensaries with the same testing, packaging, and labeling requirements as marijuana products. The law effectively eliminated the separate hemp market for intoxicating products in Colorado. California took a similar approach with AB 45, signed into law in October 2023, which required all hemp products containing detectable total THC to comply with the state's cannabis regulatory framework administered by the Department of Cannabis Control. The law established a January 1, 2025 compliance deadline, forcing retailers to remove non-compliant products from shelves or obtain cannabis licenses. Other states pursued outright bans. Arkansas, Iowa, and Utah prohibited the sale of any hemp-derived cannabinoid products intended for intoxication. These states defined prohibited products broadly to include delta-8 THC, delta-10 THC, THC-O, THCP, and THCA in any concentration. A third category of states implemented age restrictions, testing requirements, and labeling standards without full integration into marijuana regulatory systems. Minnesota enacted legislation in 2023 establishing a separate regulatory framework for "hemp-derived consumer products" containing cannabinoids, with potency limits of 5 mg THC per serving and 50 mg per package for edibles, mandatory testing for contaminants and potency, and child-resistant packaging requirements.

2025-2026: Federal Inaction and Continued State Experimentation

As of July 2026, Congress has not amended the 2018 Farm Bill's hemp provisions despite multiple proposed bills. The Hemp and Hemp-Derived CBD Consumer Protection Act, introduced in 2024, would have directed FDA to establish regulations for hemp-derived CBD in food and dietary supplements within two years, but the bill did not advance beyond committee. The absence of federal action has reinforced state primacy in regulating hemp-derived cannabinoid products. USDA finalized its hemp production rule on January 19, 2021, with minor modifications to the interim rule, but the agency's jurisdiction extends only to cultivation and does not cover processing, manufacturing, or retail sales of hemp-derived products. The FDA has maintained its position that CBD cannot be legally added to food or marketed as a dietary supplement without agency approval, but enforcement has been limited to warning letters targeting companies making therapeutic claims. The regulatory vacuum has enabled continued state-level experimentation. In 2025, Oregon enacted comprehensive regulations for hemp-derived cannabinoid products establishing a tiered system based on THC content, with products containing less than 0.5 mg THC per serving subject to minimal regulation and products containing higher amounts subject to testing, labeling, and licensed-retailer requirements. The Oregon approach has been studied by other states seeking middle-ground frameworks between prohibition and full integration with marijuana regulations.

Key Players

U.S. Department of Agriculture

USDA regulates hemp cultivation through approved state and tribal plans or direct federal oversight, but its jurisdiction does not extend to post-harvest processing or product manufacturing. The Agricultural Marketing Service within USDA administers the hemp production program established under the 2018 Farm Bill. As of June 2026, USDA had approved 71 state and tribal hemp production plans covering cultivation in 48 states and multiple tribal nations. The agency maintains a national hemp database tracking licensed producers and cultivation acreage. USDA's regulatory authority focuses on pre-harvest activities including licensing, land registration, THC testing protocols, and disposal of non-compliant plants. The agency requires annual reporting from states on total acreage planted, acreage harvested, and total production. According to USDA data, U.S. hemp cultivation peaked at 146,065 acres in 2021 and declined to approximately 54,152 acres in 2025 as market conditions deteriorated and regulatory uncertainty increased.

Food and Drug Administration

FDA maintains authority over hemp-derived products intended for human or animal consumption but has not established a comprehensive regulatory framework, creating ongoing legal uncertainty. The agency's position, articulated in multiple statements and warning letters since 2018, holds that CBD cannot be legally marketed in food or dietary supplements because it was investigated as a new drug before being marketed in foods. This interpretation stems from the drug exclusion rule in the Federal Food, Drug, and Cosmetic Act. FDA approved Epidiolex, a CBD-based drug for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, in June 2018. The agency argues that this drug approval triggered the exclusion rule, prohibiting CBD in food and supplements. However, FDA has not pursued significant enforcement actions against the thousands of companies selling CBD products, focusing instead on warning letters to companies making unsubstantiated therapeutic claims. The agency has stated that it would require substantial safety data before authorizing CBD in food or supplements, citing concerns about liver toxicity at high doses, potential drug interactions, and effects on male reproductive systems observed in animal studies. As of July 2026, FDA has not proposed regulations establishing safe use conditions for CBD or other hemp-derived cannabinoids.

Drug Enforcement Administration

DEA retains authority over controlled substances and has clarified that synthetically derived THC remains Schedule I regardless of the source material. In August 2020, DEA published an interim final rule establishing a new drug code for "tetrahydrocannabinols" that excluded THC derived from hemp as defined in the 2018 Farm Bill. However, the agency clarified that "synthetically derived" THC remains controlled in Schedule I. This distinction became critical in the delta-8 THC debate. DEA's position, articulated in a May 2022 letter to the Alabama Board of Pharmacy, stated that delta-8 THC produced through chemical synthesis from CBD is a controlled substance because it does not occur naturally in the plant in significant quantities. The agency distinguished between naturally occurring cannabinoids extracted directly from hemp and cannabinoids created through chemical conversion processes. DEA continues to register laboratories that test hemp for THC compliance under USDA's production program. The agency has not pursued enforcement actions against state-licensed hemp businesses operating in compliance with the 2018 Farm Bill, focusing instead on illicit marijuana cultivation and trafficking.

Hemp Industries Association

The Hemp Industries Association, a national trade organization representing hemp businesses, has advocated for federal regulatory clarity and opposed state-level restrictions on hemp-derived cannabinoids. The organization argues that the 2018 Farm Bill legalized all hemp derivatives containing no more than 0.3% delta-9 THC and that state restrictions undermine the federal framework and interstate commerce. The association has filed comments with USDA and FDA urging federal agencies to establish clear regulations for hemp-derived products. In 2024, the organization published model state legislation proposing age restrictions, testing requirements, and labeling standards for hemp-derived cannabinoid products as an alternative to outright bans or integration with marijuana regulatory systems.

U.S. Hemp Roundtable

The U.S. Hemp Roundtable, a coalition of hemp companies and stakeholders, has focused advocacy efforts on FDA regulation of CBD and federal legislation to establish a national framework for hemp-derived cannabinoid products. The organization supported the Hemp and Hemp-Derived CBD Consumer Protection Act and has called for Congress to direct FDA to establish regulations within a specified timeframe. The Roundtable has taken a more cautious position on intoxicating hemp-derived cannabinoids than the Hemp Industries Association, acknowledging state concerns about unregulated intoxicating products and supporting reasonable restrictions including age limits, potency caps, and testing requirements.

National Association of State Departments of Agriculture

NASDA represents state agriculture departments in policy discussions with federal agencies and has played a coordinating role in hemp regulation. The organization has emphasized the need for consistent testing protocols, realistic THC thresholds that account for measurement uncertainty, and federal support for hemp market development. NASDA has not taken a formal position on state restrictions on hemp-derived intoxicating cannabinoids, recognizing that its members have adopted divergent approaches.

Multi-State Operators

Several companies operate hemp businesses across multiple states and have been forced to adapt to varying state regulations. Curaleaf, a multi-state marijuana operator, also operates a hemp division that has navigated state-specific compliance requirements. The company has advocated for federal regulatory clarity while adapting its product formulations and distribution strategies to comply with state restrictions. Charlotte's Web, a prominent CBD company, has focused on non-intoxicating CBD products and supported federal FDA regulation. The company has generally avoided delta-8 THC and other intoxicating hemp-derived cannabinoids, positioning itself in the wellness segment rather than the intoxicating products market.

Legal and Regulatory Framework

The legal framework for hemp regulation combines federal baseline standards with extensive state authority, creating a complex multi-jurisdictional system. The Agriculture Improvement Act of 2018, codified at 7 U.S.C. § 1639o et seq., established the federal definition of hemp and removed it from the Controlled Substances Act. Section 297A defines hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition is critical because it determines what is federally legal. Products derived from cannabis plants exceeding 0.3% delta-9 THC remain marijuana under federal law and are subject to the Controlled Substances Act's Schedule I classification. The 0.3% threshold applies to the plant material itself, not to finished products, creating ambiguity about whether concentrated extracts or isolated cannabinoids derived from compliant hemp remain legal. Section 297B of the statute authorizes states and Indian tribes to submit plans to USDA for regulating hemp production within their jurisdictions. State plans must include procedures for maintaining information on land where hemp is produced, testing THC levels, disposing of plants exceeding the 0.3% threshold, licensing producers, and conducting annual inspections. USDA reviews submitted plans and approves them if they meet federal requirements. Section 297C explicitly preserves state authority to regulate hemp more restrictively than federal law. The provision states: "Nothing in this subtitle preempts or limits any law of a State or Indian Tribe that regulates the production of hemp and is more stringent than this subtitle." This clause has been interpreted to authorize states to ban hemp production entirely, impose additional testing or licensing requirements, or restrict hemp-derived products. The Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. § 301 et seq., grants FDA authority over food, drugs, dietary supplements, and cosmetics. Section 321(ff) prohibits marketing a substance as a dietary supplement if it was approved as a new drug or authorized for investigation as a new drug before being marketed as a supplement. FDA has applied this exclusion rule to CBD based on Epidiolex's drug approval, creating the ongoing regulatory impasse. State laws vary dramatically in their approach to hemp-derived cannabinoids. Some states have amended their controlled substances statutes to exclude all hemp derivatives meeting the federal definition. Others have created separate regulatory frameworks for hemp products. Still others have maintained or enacted restrictions on specific cannabinoids or product types. The Uniform Controlled Substances Act, adopted in various forms by most states, classifies THC as a Schedule I controlled substance. States that have not explicitly amended their controlled substances laws to exclude hemp-derived THC face legal ambiguity about whether delta-8 THC and other hemp-derived cannabinoids remain prohibited under pre-existing state law. Interstate commerce protections under the U.S. Constitution's Commerce Clause, Article I, Section 8, generally prohibit states from discriminating against out-of-state products. However, courts have recognized exceptions for state regulations addressing legitimate health and safety concerns. No federal court has definitively ruled on whether state restrictions on hemp-derived intoxicating cannabinoids violate the Commerce Clause, though several lawsuits are pending as of July 2026.

State-by-State Breakdown

Hemp regulation varies dramatically across states, with approaches ranging from outright bans on intoxicating hemp-derived cannabinoids to permissive frameworks with minimal restrictions.

Alabama

Alabama prohibits the sale of hemp-derived products containing delta-8 THC, delta-10 THC, or other intoxicating cannabinoids. The Alabama Board of Pharmacy issued guidance in 2021 classifying delta-8 THC as a Schedule I controlled substance under state law. Legislation enacted in 2022 codified this position, explicitly excluding intoxicating hemp-derived cannabinoids from the state's hemp program. Non-intoxicating CBD products remain legal with no specific potency limits or testing requirements for retail sales.

Alaska

Alaska has not enacted specific restrictions on hemp-derived cannabinoids beyond federal requirements. The state's hemp program, administered by the Department of Natural Resources, regulates cultivation but does not impose additional requirements on processors or retailers. Delta-8 THC and other hemp-derived cannabinoids are sold in retail stores without state-specific testing or labeling mandates, though products must comply with federal standards including the 0.3% delta-9 THC limit.

Arizona

Arizona enacted legislation in 2021 requiring hemp-derived products containing more than 0.3% total THC to be sold only through licensed marijuana dispensaries. The law defines total THC to include delta-9 THC, delta-8 THC, and THCA, using a calculation method similar to USDA's hemp testing protocol. Products meeting the federal hemp definition with 0.3% or less total THC can be sold in general retail without specific state licensing, but must include labeling disclosing cannabinoid content.

Arkansas

Arkansas prohibits the sale of any hemp-derived product intended for intoxication. The Arkansas Department of Health issued emergency rules in 2021 banning delta-8 THC products, and the state legislature codified the ban in 2022. The law prohibits manufacturing, distributing, or selling any hemp-derived cannabinoid product marketed for intoxicating effects, regardless of THC content. Non-intoxicating CBD products remain legal, though the state has not established clear criteria for distinguishing intoxicating from non-intoxicating products.

California

California enacted AB 45 in 2023, requiring all hemp products containing detectable amounts of total THC to comply with the state's cannabis regulatory framework administered by the Department of Cannabis Control. The law established a January 1, 2025 compliance deadline. Products containing any detectable THC must be manufactured by licensed cannabis businesses, tested by licensed laboratories for potency and contaminants, packaged in child-resistant containers with state-mandated warnings, and sold only through licensed cannabis retailers to customers 21 and older. The law effectively eliminated the separate hemp market for products containing THC in California, though non-detectable THC hemp products can still be sold in general retail.

Colorado

Colorado enacted HB 22-1317 in 2022, establishing a regulatory framework for "industrial hemp products" containing more than 0.3% total THC. The law requires such products to be sold only through licensed marijuana dispensaries with the same testing, packaging, and labeling requirements as marijuana products. Products containing 0.3% or less total THC can be sold in general retail but must comply with testing requirements for contaminants and potency verification. The Colorado Department of Public Health and Environment administers the industrial hemp program, while the Marijuana Enforcement Division regulates higher-THC products.

Connecticut

Connecticut prohibits the sale of hemp-derived products containing delta-8 THC or other intoxicating cannabinoids outside the state's regulated marijuana market. Legislation enacted in 2022 classified delta-8 THC and similar cannabinoids as marijuana under state law, requiring them to be sold through licensed dispensaries. The state's hemp program, administered by the Department of Agriculture, regulates cultivation and allows sales of non-intoxicating CBD products without specific potency limits.

Delaware

Delaware has not enacted specific restrictions on hemp-derived cannabinoids beyond federal requirements. The state's hemp program regulates cultivation, and hemp-derived products including delta-8 THC are sold in retail stores. The state has not established testing requirements or potency limits for hemp-derived cannabinoid products sold at retail.

Florida

Florida maintains a permissive framework for hemp-derived cannabinoids with minimal state-specific restrictions. The state's hemp program, administered by the Department of Agriculture and Consumer Services, regulates cultivation and requires hemp extract manufacturers to register with the state. Products must contain no more than 0.3% delta-9 THC and must include labeling disclosing total THC content and a QR code linking to a certificate of analysis. The state has not banned delta-8 THC or other hemp-derived intoxicating cannabinoids, though legislation to impose restrictions has been proposed multiple times. As of July 2026, Florida remains one of the largest markets for hemp-derived cannabinoid products.

Georgia

Georgia allows the sale of hemp-derived CBD products under its Low THC Oil program but has not established clear regulations for delta-8 THC and other hemp-derived cannabinoids. The state's hemp program regulates cultivation, and the Georgia Department Agriculture has issued guidance stating that hemp-derived products must comply with federal law. Delta-8 THC products are sold in retail stores, though the legal status remains somewhat ambiguous under state law.

Hawaii

Hawaii enacted legislation in 2021 prohibiting the sale of hemp-derived products containing delta-8 THC, delta-10 THC, or other intoxicating cannabinoids. The law requires all hemp products sold in the state to contain no more than 0.3% total THC, including all THC isomers. The Hawaii Department of Health administers regulations for hemp-derived products, requiring manufacturers to register and submit products for testing before retail sales.

Idaho

Idaho has not adopted a hemp program and maintains that all cannabis derivatives containing any amount of THC remain illegal under state law. The state's controlled substances statute does not include an exception for federally compliant hemp, creating a conflict with federal law. Idaho law enforcement has prosecuted individuals for possession of CBD products containing trace amounts of THC. Legislation to establish a hemp program has been proposed but has not advanced.

Illinois

Illinois requires hemp-derived products containing delta-8 THC or other intoxicating cannabinoids to be sold only through licensed marijuana dispensaries. The Illinois Department of Agriculture regulates hemp cultivation, while the Department of Financial and Professional Regulation oversees marijuana dispensaries. Products sold through dispensaries must comply with testing requirements for potency and contaminants. Non-intoxicating CBD products can be sold in general retail without specific state licensing.

Indiana

Indiana allows the sale of hemp-derived CBD products but has taken enforcement action against delta-8 THC products. The state's controlled substances statute classifies all THC isomers as Schedule I substances, and the state has not explicitly exempted hemp-derived THC. The Indiana State Department of Health has issued guidance stating that delta-8 THC remains illegal under state law. However, delta-8 THC products continue to be sold in some retail locations, and enforcement has been inconsistent.

Iowa

Iowa prohibits the sale of hemp-derived products containing delta-8 THC or other intoxicating cannabinoids. The Iowa Department of Agriculture and Land Stewardship issued guidance in 2021 stating that delta-8 THC is not a legal hemp product under state law. Legislation enacted in 2022 codified this position, explicitly excluding intoxicating hemp-derived cannabinoids from the state's hemp program. Non-intoxicating CBD products remain legal.

Kansas

Kansas has not adopted a hemp program and maintains restrictive policies on cannabis derivatives. The state's controlled substances statute classifies THC as a Schedule I substance without an exception for federally compliant hemp. However, Kansas enacted legislation in 2018 legalizing CBD products containing no more than 0.3% THC, creating a narrow exception. The legal status of delta-8 THC and other hemp-derived cannabinoids remains unclear under state law.

Kentucky

Kentucky maintains a permissive framework for hemp-derived cannabinoids with minimal state-specific restrictions beyond federal requirements. The state pioneered hemp cultivation under the 2014 Farm Bill pilot program and has developed a robust hemp industry. The Kentucky Department of Agriculture regulates hemp cultivation and processing. Delta-8 THC and other hemp-derived cannabinoids are sold in retail stores without state-specific testing mandates or potency limits, though products must comply with federal standards.

Louisiana

Louisiana enacted legislation in 2022 establishing regulations for hemp-derived products containing THC. The law requires products to be tested for potency and contaminants, limits serving sizes to 8 mg THC for edibles, and requires child-resistant packaging and labeling warnings. The Louisiana Department of Agriculture and Forestry administers the hemp program and has established testing protocols for hemp-derived products. Products must be sold to individuals 21 and older.

Maine

Maine requires hemp-derived products containing intoxicating cannabinoids to comply with the state's marijuana regulatory framework. The Maine Department of Agriculture, Conservation and Forestry regulates hemp cultivation, while the Office of Cannabis Policy regulates marijuana and intoxicating hemp products. Products containing more than 0.3% total THC must be manufactured by licensed cannabis businesses and sold through licensed retailers. Non-intoxicating CBD products can be sold in general retail.

Maryland

Maryland has not enacted specific restrictions on hemp-derived cannabinoids beyond federal requirements. The state's hemp program, administered by the Department of Agriculture, regulates cultivation. Delta-8 THC and other hemp-derived cannabinoids are sold in retail stores. However, legislation to regulate or restrict intoxicating hemp-derived cannabinoids has been proposed and may be enacted in future legislative sessions.

Massachusetts

Massachusetts requires hemp-derived products containing intoxicating amounts of THC to be sold only through licensed marijuana dispensaries. The Massachusetts Cannabis Control Commission issued guidance in 2021 stating that products marketed for intoxicating effects must comply with the state's marijuana regulations regardless of whether they are derived from hemp or marijuana. The state's hemp program, administered by the Department of Agricultural Resources, regulates cultivation of non-intoxicating hemp.

Michigan

Michigan allows the sale of hemp-derived cannabinoids in general retail with minimal state-specific restrictions. The state's hemp program, administered by the Department of Agriculture and Rural Development, regulates cultivation and requires processors to obtain licenses. Delta-8 THC and other hemp-derived cannabinoids are sold widely. The state has not established specific testing requirements or potency limits for hemp-derived products, though products must comply with federal standards.

Minnesota

Minnesota enacted comprehensive legislation in 2023 establishing a regulatory framework for "hemp-derived consumer products" containing cannabinoids. The law limits edible products to 5 mg THC per serving and 50 mg per package, requires testing for potency and contaminants, mandates child-resistant packaging and labeling warnings, and requires retailers to verify purchasers are 21 or older. The Minnesota Board of Pharmacy administers the regulatory program. The law created a middle-ground approach between prohibition and full integration with marijuana regulations.

Mississippi

Mississippi prohibits the sale of hemp-derived products containing delta-8 THC or other intoxicating cannabinoids. The Mississippi Department of Agriculture and Commerce issued guidance in 2021 stating that delta-8 THC is not a legal hemp product under state law. The state's hemp program regulates cultivation of non-intoxicating hemp. Non-intoxicating CBD products remain legal.

Missouri

Missouri maintains a permissive framework for hemp-derived cannabinoids with minimal state-specific restrictions. The state's hemp program, administered by the Department of Agriculture, regulates cultivation and requires processors to register. Delta-8 THC and other hemp-derived cannabinoids are sold in retail stores without state-specific testing mandates or potency limits. Products must comply with federal standards including the 0.3% delta-9 THC limit.

Montana

Montana enacted legislation in 2021 prohibiting the sale of hemp-derived products containing delta-8 THC or other intoxicating cannabinoids outside the state's regulated marijuana market. The law requires intoxicating cannabinoid products to be sold only through licensed marijuana dispensaries with testing and labeling requirements. The Montana Department of Agriculture regulates hemp cultivation for non-intoxicating products.

Nebraska

Nebraska has not adopted a hemp program and maintains that cannabis derivatives containing THC remain illegal under state law. However, Nebraska enacted legislation in 2020 legalizing CBD products containing no more than 0.3% THC, creating a narrow exception. The legal status of delta-8 THC and other hemp-derived cannabinoids remains unclear, and enforcement has been inconsistent.

Nevada

Nevada requires hemp-derived products containing intoxicating cannabinoids to be sold only through licensed marijuana dispensaries. The Nevada Department of Agriculture regulates hemp cultivation, while the Cannabis Compliance Board regulates marijuana and intoxicating hemp products. Products sold through dispensaries must comply with testing requirements for potency and contaminants. Non-intoxicating CBD products can be sold in general retail.

New Hampshire

New Hampshire allows the sale of hemp-derived cannabinoids in general retail with minimal state-specific restrictions. The state's hemp program, administered by the Department of Agriculture, Markets and Food, regulates cultivation. Delta-8 THC and other hemp-derived cannabinoids are